Serum concentration of tumor necrosis factor in patients with breast cancer

Shyr Ming Sheen-Chen, Wei Jen Chen, Hock Liew Eng, Fong Fu Chou

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: The outcome of breast cancer is usually determined by multiple factors. Serum tumor necrosis factor alpha concentration has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim to investigate any correlation between the serum tumor necrosis factor alpha and the clinicopathological fetures and furthermore evaluate the prognostic significance of serum tumor necrosis factor alpha concentration in breast cancer. Methods: Forty consecutive patients with invasive breast cancer undergoing modified radical mastectomy were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted 30 healthy, age-matched subjects. Serum concentrations of tumor necrosis factor alpha were measured by the quantitative sandwich enzyme immunoassay technique. The data on tumor size, age, estrogen receptor status, lymph node status and TNM staging were reviewed and recorded. Results: The mean value of serum tumor necrosis factor alpha in patients with invasive breast cancer was 1.47 ± 0.58 pg/ml and that of the control group was 0.98 ± 0.37 pg/ml, and the difference was significant (P < 0.01). With univariable analysis, patients with maximum tumor size of 5 cm or larger (P = 0.03), more advanced TNM staging (P < 0.01); and more advanced lymph node status (P < 0.01) were shown to have significantly higher serum concentrations of tumor necrosis factor alpha. However, with multivariable analysis, TNM staging appeared as the only independent factor (P < 0.01) predicting the significant, higher serum concentrations of tumor necrosis factor alpha. Conclusion: Preoperative evaluation of serum tumor necrosis factor alpha concentrations may be a valuable parameter for reflecting the severity of staging for invasive breast cancer.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalBreast Cancer Research and Treatment
Volume43
Issue number3
DOIs
Publication statusPublished - May 6 1997
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Breast Neoplasms
Serum
Neoplasm Staging
Lymph Nodes
Modified Radical Mastectomy
Neoplasms
Control Groups
Immunoenzyme Techniques
Centrifugation
Estrogen Receptors

Keywords

  • Breast cancer
  • Mastectomy
  • Prognosis
  • Serum markers
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum concentration of tumor necrosis factor in patients with breast cancer. / Sheen-Chen, Shyr Ming; Chen, Wei Jen; Eng, Hock Liew; Chou, Fong Fu.

In: Breast Cancer Research and Treatment, Vol. 43, No. 3, 06.05.1997, p. 211-215.

Research output: Contribution to journalArticle

Sheen-Chen, Shyr Ming ; Chen, Wei Jen ; Eng, Hock Liew ; Chou, Fong Fu. / Serum concentration of tumor necrosis factor in patients with breast cancer. In: Breast Cancer Research and Treatment. 1997 ; Vol. 43, No. 3. pp. 211-215.
@article{c8c032fb67b64850a0b741dde1e82c5e,
title = "Serum concentration of tumor necrosis factor in patients with breast cancer",
abstract = "Background: The outcome of breast cancer is usually determined by multiple factors. Serum tumor necrosis factor alpha concentration has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim to investigate any correlation between the serum tumor necrosis factor alpha and the clinicopathological fetures and furthermore evaluate the prognostic significance of serum tumor necrosis factor alpha concentration in breast cancer. Methods: Forty consecutive patients with invasive breast cancer undergoing modified radical mastectomy were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted 30 healthy, age-matched subjects. Serum concentrations of tumor necrosis factor alpha were measured by the quantitative sandwich enzyme immunoassay technique. The data on tumor size, age, estrogen receptor status, lymph node status and TNM staging were reviewed and recorded. Results: The mean value of serum tumor necrosis factor alpha in patients with invasive breast cancer was 1.47 ± 0.58 pg/ml and that of the control group was 0.98 ± 0.37 pg/ml, and the difference was significant (P < 0.01). With univariable analysis, patients with maximum tumor size of 5 cm or larger (P = 0.03), more advanced TNM staging (P < 0.01); and more advanced lymph node status (P < 0.01) were shown to have significantly higher serum concentrations of tumor necrosis factor alpha. However, with multivariable analysis, TNM staging appeared as the only independent factor (P < 0.01) predicting the significant, higher serum concentrations of tumor necrosis factor alpha. Conclusion: Preoperative evaluation of serum tumor necrosis factor alpha concentrations may be a valuable parameter for reflecting the severity of staging for invasive breast cancer.",
keywords = "Breast cancer, Mastectomy, Prognosis, Serum markers, Tumor necrosis factor",
author = "Sheen-Chen, {Shyr Ming} and Chen, {Wei Jen} and Eng, {Hock Liew} and Chou, {Fong Fu}",
year = "1997",
month = "5",
day = "6",
doi = "10.1023/A:1005736712307",
language = "English",
volume = "43",
pages = "211--215",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Serum concentration of tumor necrosis factor in patients with breast cancer

AU - Sheen-Chen, Shyr Ming

AU - Chen, Wei Jen

AU - Eng, Hock Liew

AU - Chou, Fong Fu

PY - 1997/5/6

Y1 - 1997/5/6

N2 - Background: The outcome of breast cancer is usually determined by multiple factors. Serum tumor necrosis factor alpha concentration has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim to investigate any correlation between the serum tumor necrosis factor alpha and the clinicopathological fetures and furthermore evaluate the prognostic significance of serum tumor necrosis factor alpha concentration in breast cancer. Methods: Forty consecutive patients with invasive breast cancer undergoing modified radical mastectomy were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted 30 healthy, age-matched subjects. Serum concentrations of tumor necrosis factor alpha were measured by the quantitative sandwich enzyme immunoassay technique. The data on tumor size, age, estrogen receptor status, lymph node status and TNM staging were reviewed and recorded. Results: The mean value of serum tumor necrosis factor alpha in patients with invasive breast cancer was 1.47 ± 0.58 pg/ml and that of the control group was 0.98 ± 0.37 pg/ml, and the difference was significant (P < 0.01). With univariable analysis, patients with maximum tumor size of 5 cm or larger (P = 0.03), more advanced TNM staging (P < 0.01); and more advanced lymph node status (P < 0.01) were shown to have significantly higher serum concentrations of tumor necrosis factor alpha. However, with multivariable analysis, TNM staging appeared as the only independent factor (P < 0.01) predicting the significant, higher serum concentrations of tumor necrosis factor alpha. Conclusion: Preoperative evaluation of serum tumor necrosis factor alpha concentrations may be a valuable parameter for reflecting the severity of staging for invasive breast cancer.

AB - Background: The outcome of breast cancer is usually determined by multiple factors. Serum tumor necrosis factor alpha concentration has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim to investigate any correlation between the serum tumor necrosis factor alpha and the clinicopathological fetures and furthermore evaluate the prognostic significance of serum tumor necrosis factor alpha concentration in breast cancer. Methods: Forty consecutive patients with invasive breast cancer undergoing modified radical mastectomy were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and stored at -70°C until assayed. The control group consisted 30 healthy, age-matched subjects. Serum concentrations of tumor necrosis factor alpha were measured by the quantitative sandwich enzyme immunoassay technique. The data on tumor size, age, estrogen receptor status, lymph node status and TNM staging were reviewed and recorded. Results: The mean value of serum tumor necrosis factor alpha in patients with invasive breast cancer was 1.47 ± 0.58 pg/ml and that of the control group was 0.98 ± 0.37 pg/ml, and the difference was significant (P < 0.01). With univariable analysis, patients with maximum tumor size of 5 cm or larger (P = 0.03), more advanced TNM staging (P < 0.01); and more advanced lymph node status (P < 0.01) were shown to have significantly higher serum concentrations of tumor necrosis factor alpha. However, with multivariable analysis, TNM staging appeared as the only independent factor (P < 0.01) predicting the significant, higher serum concentrations of tumor necrosis factor alpha. Conclusion: Preoperative evaluation of serum tumor necrosis factor alpha concentrations may be a valuable parameter for reflecting the severity of staging for invasive breast cancer.

KW - Breast cancer

KW - Mastectomy

KW - Prognosis

KW - Serum markers

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0030905416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030905416&partnerID=8YFLogxK

U2 - 10.1023/A:1005736712307

DO - 10.1023/A:1005736712307

M3 - Article

C2 - 9150900

AN - SCOPUS:0030905416

VL - 43

SP - 211

EP - 215

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -